All News
ACR21 Best Abstracts - Day 1
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Read Article
Opening Day Report
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
Read Article
Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21
👉🏼~1000 pts
👉🏼Severe outcomes esp in #GCA and #AAV
👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes
@RheumNow
https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL
Mrinalini Dey DrMiniDey ( View Tweet)
‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7
Janet Pope Janetbirdope ( View Tweet)
@SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct
Richard Conway RichardPAConway ( View Tweet)
So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face.
Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work!
#ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM
David Liew drdavidliew ( View Tweet)
Factors associated w/ poor COVID19 outcomes in #SLE from the GRA @rheum_covid
📌Demographics - age, sex, region
📌Glucocorticoid use
📌 Comorbids - renal, CV
📌Untreated/active dse
❗Very important msg here: Control dse, manage comorbids & avoid GCs
@RheumNow #ACR21 abs0866 https://t.co/eXR3KqGrJa
sheila RHEUMarampa ( View Tweet)
Good news for #COVID vaccine in #SLE. ✅doesn’t cause #lupus flares ➡️ no increase in APS. What about #SARS-CoV2 infection in SLE. Flares ↔️ stable but ⬆️APS Abs. from Hopkins cohort. Petri #ACRBest #ACR21 abst0858 @RheumNow https://t.co/ABx4C4lwvs
Janet Pope Janetbirdope ( View Tweet)
Thank you ACR Convergence Today for the interview and featuring my abstract ! #ACR21 @ACRheum
https://t.co/JISSTSDt1d https://t.co/roh5BSgbeD
Links:
Akhil Sood MD AkhilSoodMD ( View Tweet)
Exciting day at #ACR21
I wrote an article discussing COVID 19 in #RheumatoidArthritis discussing the following abstracts
0097 by Hasseli
1445 by @NamrataRheum
L04 by @rheum_cat & @rheum_covid
@rheumnow #COVID19 #RA #JAK #Rituximab
https://t.co/g32ZYHBjQY
Akhil Sood MD AkhilSoodMD ( View Tweet)
Dr. Petri noted that 1 week off of immunosuppressants is adequate for most lupus patients to mount a response. She avoided RTX during the pandemic. In pts who have had inadequate response to 2 or 3 doses of mRNA, she switches them to J&J. #ACR21 #COVI19 CH @rheumnow https://t.co/qNjmx9uTLF
TheDaoIndex KDAO2011 ( View Tweet)
HSS Study of 136 SLE flares post-vax:
👉100 (74%) w/expected AE (headache/myalgias)
👉11 (8.1%) pts with SLE flare
👉Majority of flares were mild-mod & occurred w/in 1 week of vaccination
👉Most resolved w/in 7 days.
Abst#0896 #ACR21 @rheumnow
https://t.co/e6AP8PPRH2
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 #Abstr0437 OK, so RTX affects #COVID vaccine but some pts need RTX. Factors predicting response to vaccine:
RA vs AAV/IIM
Higher IgG
Longer time-to-RTX
Lower RTX courses Number.
Prediction Calculator is developed but need ext. validation #RheumNow https://t.co/iXSaGQ76hS https://t.co/WQAV3GRPBz
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 Ignaki Sanz makes the case that +++ AUTOANTIBODIES are integrally involved in #COVID19 immunopathogeneisis and may rise and fall w disease states- TBD what role they play in acute disease and #LongCovid @CCalabreseDO @VirusesImmunity @CleClinicMD #COVID19AB https://t.co/9dzCSh5V7R
Leonard Calabrese LCalabreseDO ( View Tweet)
Dr. P Krause (FDA/CBER Deputy Dir., Office of Vaccine Research and Review) on #COVIDvaccine in kids:
👉Children respond to vaccine better than adults; can use lower doses
👉the lower dose will mitigate safety concerns
(FDA gave EUA for Pfizer vaccine for 5-11 yo) #ACR21 https://t.co/Z7kcYQKZ8S
TheDaoIndex KDAO2011 ( View Tweet)
👉 anti-CK Ab may be a cause of #LongCovid syndrome
👉found in patients with autoimmune (SLE/Sjogrens) and can affect dz severity.
👉has not been seen in children
2/2
#ACR21
TheDaoIndex KDAO2011 ( View Tweet)
In case you missed it. @ACRheum #COVIDvaccine guidance v 4.0 for Rheum patients & what's added:
👉3rd dose recommend, timing relative to meds (as before)
👉mRNA booster preferred if initial doses were mRNA
👉mAb as PrEP/Rx for high risk pts
https://t.co/R8K8WeZBMt
TheDaoIndex KDAO2011 ( View Tweet)
Abst#0858 Hopkins SLE Cohort 860 pts, 65 w/COVID19, 228 vax'd:
👉COVID19 infx did not increase dz activity, but aPLs were increased (rash decreased likely d/t quarantine and no sun exposure)
👉COVID19 vaccine did not affect dz activity #ACR21 @rheumnow
https://t.co/C65qJuMIbk
TheDaoIndex KDAO2011 ( View Tweet)
So fitting that @ACRheum President @DrDavidKarp has highlighted the amazing work of @rheum_covid in the #ACR21 Opening Session.
In crazy times, it delivered results with unprecedented speed, when our patients needed it most. We will look back in history with thanks.
@RheumNow https://t.co/cTnAZP9UDl
David Liew drdavidliew ( View Tweet)
Abst 0501
Kakkar & colleagues examined immunogenicity of single dose of SARS-CoV-2 Vaccine in patients with systemic sclerosis
- Vaccine is safe
- Immunosuppression lowered Ab production but no effect on T cell response
#ACR21 @RheumNow https://t.co/NsLrWHh7ZS
Akhil Sood MD AkhilSoodMD ( View Tweet)
